Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 3/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14439650 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL15888952 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL26355806 | 0.85 | ALDH1A1 (0.45) | FOLH1ALDH1A1TSHR | |
| SCHEMBL15083489 | 0.81 | CTSK (0.46) | ALDH1A1TSHR | |
| SCHEMBL16288146 | 0.81 | CTSK (0.46) | ALDH1A1TSHR | |
| SCHEMBL13448062 | 0.81 | FOLH1 (0.39) | FOLH1ALBNOD1TSHR | |
| SCHEMBL16446180 | 0.81 | FOLH1 (0.39) | FOLH1ALBNOD1TSHR | |
| SCHEMBL24630046 | 0.80 | NOD1 (0.48) | FOLH1ALBNOD1 | |
| SCHEMBL29072118 | 0.80 | NOD1 (0.48) | FOLH1ALBNOD1 | |
| SCHEMBL29072117 | 0.80 | NOD1 (0.48) | FOLH1ALBNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | SLC43A1, ABCB1, NAPA | FOLH1 196/4885TGM2 2262/4885ALB 1012/4885 |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | FOLH1 47/4885TGM2 1483/4885ALB 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.